Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The safety profile was described as manageable, though not without notable toxicities
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
Fertility platform launches flagship clinic with advanced IVF tech
The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care
While overall survival data remain immature, the results pointed to a favourable trend.
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Subscribe To Our Newsletter & Stay Updated
